Abstract
Guidelines for the pharmacologic and nonpharmacologic management of hypertension were first published in the 1970s and subsequently revised in the 1980s and 1990s. In this review, we focus on guideline modifications of the past 20 years and describe the main similarities and differences between the guidelines recently published by the World Health Organization/International Society of Hypertension committees and the US Joint National Committee. These guidelines agree on fundamental issues such as the careful assessment of patients' overall risk and target-organ damage, the treatment of elderly hypertensive individuals and isolated systolic hypertension, and the importance of persistent blood pressure reduction below 140 90 mm Hg. The committees also disagree in a few areas, such as the class of drugs to be used as first-line treatment and the use of ambulatory blood pressure monitoring. These disagreements reflect the limited scientific evidence on these specific topics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
